Histological characteristics of complement deposition in NMOSD, MOGAD and MS

被引：0
|
作者：
Takai, Yoshiki [1 ,2 ]
Hametner, Simon [3 ]
Riedl, Christian [3 ]
Misu, Tatsuro [1 ]
Fujihara, Kazuo [4 ]
Hoeftberger, Romana [3 ]
机构：
[1] Tohoku Univ Hosp, Neurol, Sendai, Miyagi, Japan
[2] Tohoku Univ Hosp, Pathol, Sendai, Miyagi, Japan
[3] Med Univ Vienna, Div Neuropathol & Neurochem, Dept Neurol, Vienna, Austria
[4] Fukushima Med Univ, Multiple Sclerosis Therapeut, Fukushima, Japan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O075/2087
引用
收藏
页码：71 / 72
页数：2
相关论文
共 50 条
  • [1] Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD
    Redenbaugh, Vyanka
    Flanagan, Eoin P.
    NEUROTHERAPEUTICS, 2022, 19 (03) : 808 - 822
  • [2] Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD
    Vyanka Redenbaugh
    Eoin P. Flanagan
    Neurotherapeutics, 2022, 19 : 808 - 822
  • [3] Periventricular gradients in NAWM abnormalities differ in MS, NMOSD and MOGAD
    Sun, Jun
    Xu, Siyao
    Tian, Decai
    Duan, Yunyun
    Xu, Xiaolu
    Lv, Shan
    Cao, Guanmei
    Shi, Fu-Dong
    Chard, Declan
    Barkhof, Frederik
    Zhuo, Zhizheng
    Zhang, Xinghu
    Liu, Yaou
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 75
  • [4] Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD
    Ramirez, Deyanira A.
    Gracia, Fernando
    Jimenez, Alejandro J. Diaz
    Alvarez, Priscilla Monterrey
    Candelario, Awilda E.
    Castro-Escobar, Romy
    Rivas, Anyeri I. de Pena
    de la Fe, Amado Diaz
    Camano, David R. Dondis
    Sotelo, Octavio A. Duarte
    Valle, Luis A. Garcia
    Juarez, Gloria M. A. Gramajo
    Torres, Ericka Lopez
    Vindas, Alexander Parajeles
    Rivera, Ligia I. Portillo
    Sanchez, Nicia E. Ramirez
    Salinas, Luis C. Rodriguez
    Pujols, Biany Santos
    Santana, Sarah B. Vargas
    Angeles, Indhira Zabala
    Pena, Joaquin A.
    Rivera, Victor M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2025, 95
  • [5] Quantitative MRI measures of MOGAD compared to MS, NMOSD and healthy controls
    Kunchok, A.
    Ontaneda, D.
    Abbatemarco, J.
    Cohen, J. A.
    Nakamura, K.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 424 - 425
  • [6] Targeting B cells to modify MS, NMOSD, and MOGAD Part 2
    Graf, Jonas
    Mares, Jan
    Barnett, Michael
    Aktas, Orhan
    Albrecht, Philipp
    Zamvil, Scott S.
    Hartung, Hans-Peter
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (01):
  • [7] Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
    Lin, Liuyu
    Wu, Yuqing
    Hang, Hailun
    Lu, Jie
    Ding, Yuanliang
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] symptomatic Lesions in MOGAD and NMOSD
    Yuen, N.
    Perrier, R. L.
    Casserly, C. S.
    Morrow, S. A.
    Racosta, J. M.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 161 - 161
  • [9] Is there truly no progression in NMOSD and MOGAD?
    Lechner-Scott, J.
    Giovannoni, G.
    Ch, Hawkes
    Levy, M.
    Ea, Yeh
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2025, 94
  • [10] Emerging therapies for MOGAD/NMOSD
    Burton, Jodie
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
12345